OTCMKTS:CRPOFCeapro Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ceapro Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.40 0.00 (0.00 %) (As of 07/3/2020 04:00 PM ET) Add Compare Share Today's Range$0.40Now: $0.40▼$0.4050-Day Range$0.20MA: $0.31▼$0.4052-Week Range$0.11Now: $0.40▼$0.41Volume180 shsAverage Volume4,714 shsMarket Capitalization$31.04 millionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAdvanced ChartCompetitorsEarningsHeadlinesSocial Media Ceapro, Inc. is a biotechnology company, which is involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its extracts are also used in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The company specializes in natural product chemistry, microbiology, biochemistry, immunology, and process engineering in the fields of active ingredients, biopharmaceuticals, and drug-delivery solutions. Ceapro was founded on January 1, 1997 and is headquartered in Edmonton, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Ceapro. Previous Next 2.7 Community Rank Outperform VotesCeapro has received 46 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCeapro has received 39 “underperform” votes. (Add your “underperform” vote.)Community SentimentCeapro has received 54.12% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Ceapro and other stocks. Vote “Outperform” if you believe CRPOF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRPOF will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCeapro does not currently pay a dividend.Dividend GrowthCeapro does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ceapro insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioCeapro has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CRPOF Previous Symbol CUSIPN/A CIKN/A Webwww.ceapro.com Phone780-421-4555Debt Debt-to-Equity Ratio0.12 Current Ratio6.07 Quick Ratio5.24Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.71 million Price / Sales3.20 Cash Flow$0.01 per share Price / Cash Flow58.81 Book Value$0.22 per share Price / Book1.82Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-850,000.00 Net Margins4.48% Return on Equity2.78% Return on Assets2.27%Miscellaneous EmployeesN/A Outstanding Shares77,610,000Market Cap$31.04 million Next Earnings Date8/26/2020 (Estimated) OptionableNot Optionable OTC:CRPOF Rates by TradingView Receive CRPOF News and Ratings via Email Sign-up to receive the latest news and ratings for CRPOF and its competitors with MarketBeat's FREE daily newsletter. Ceapro (OTCMKTS:CRPOF) Frequently Asked Questions How has Ceapro's stock been impacted by COVID-19 (Coronavirus)? Ceapro's stock was trading at $0.1909 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CRPOF shares have increased by 109.5% and is now trading at $0.40. View which stocks have been most impacted by Coronavirus. When is Ceapro's next earnings date? Ceapro is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for Ceapro. How were Ceapro's earnings last quarter? Ceapro Inc (OTCMKTS:CRPOF) posted its quarterly earnings results on Thursday, May, 28th. The company reported $0.01 earnings per share for the quarter. The business had revenue of $3.19 million for the quarter. Ceapro had a return on equity of 2.78% and a net margin of 4.48%. View Ceapro's earnings history. Has Ceapro been receiving favorable news coverage? News coverage about CRPOF stock has been trending somewhat negative on Friday, InfoTrie reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ceapro earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Ceapro. Who are some of Ceapro's key competitors? Some companies that are related to Ceapro include Inflarx (IFRX), Catabasis Pharmaceuticals (CATB), Conatus Pharmaceuticals (CNAT), Theratechnologies (THERF), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM), Eton Pharmaceuticals (ETON), Savara (SVRA), Axovant Gene Therapies (AXGT), Recro Pharma (REPH), Checkpoint Therapeutics (CKPT), Aptorum Group (APM), TFF Pharmaceuticals (TFFP), ContraFect (CFRX) and SUMMIT THERAPEU/S (SMMT). View all competitors. Who are Ceapro's key executives? Ceapro's management team includes the following people: Gilles R. Gagnon, President, Chief Executive Officer & DirectorStacy Prefontaine, Chief Financial Officer & SecretaryLeoni DeJoya, Vice President-Bioprocessing Business Unit What is Ceapro's stock symbol? Ceapro trades on the OTCMKTS under the ticker symbol "CRPOF." How do I buy shares of Ceapro? Shares of CRPOF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Ceapro's stock price today? One share of CRPOF stock can currently be purchased for approximately $0.40. How big of a company is Ceapro? Ceapro has a market capitalization of $31.04 million and generates $9.71 million in revenue each year. What is Ceapro's official website? The official website for Ceapro is www.ceapro.com. How can I contact Ceapro? Ceapro's mailing address is 7824 51 Avenue NW, Edmonton A0, T6E 6W2. The company can be reached via phone at 780-421-4555 or via email at [email protected] This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
